Literature DB >> 17035382

The case for a genetic predisposition to serrated neoplasia in the colorectum: hypothesis and review of the literature.

Joanne Young1, Jeremy R Jass.   

Abstract

In recent years, an alternative pathway of colorectal cancer development has been described in which serrated polyps replace the traditional adenoma as the precursor lesion. Importantly, serrated polyps and a subset of colorectal cancer show largely nonoverlapping mutation profiles to those found in adenomas and the majority of colorectal cancer. These genetic alterations include activating mutation of the BRAF proto-oncogene and widespread gene promoter hypermethylation (CpG island methylator phenotype or CIMP). Up to 15% of colorectal cancer is likely to develop on the basis of a strong genetic predisposition. The two most well-characterized syndromes, familial adenomatous polyposis and hereditary nonpolyposis colorectal cancer (Lynch syndrome), both develop via the adenoma-carcinoma pathway and together account for approximately one third of familial colorectal cancer. We have recently described 11 families in which there is evidence that the genetic predisposition to autosomal dominant colorectal cancer is linked to the serrated pathway. This condition, serrated pathway syndrome, and the related condition, hyperplastic polyposis, the presentation of which suggests a recessive mode of inheritance, represent two syndromes in which BRAF mutation and methylation co-occur within serrated precursor lesions. Further, CIMP is observed in the normal colonic mucosa of individuals with hyperplastic polyposis consistent with a field defect in epigenetic regulation. The spectrum of serrated neoplasia may also implicate the apparently sporadic and later onset subset of colorectal cancer with high levels of microsatellite instability. The tendency for these lesions to be multiple, associated with smoking, and to show frequent BRAF mutation and CIMP points to a defect that may result from interactions between the environment and a weakly penetrant genetic alteration.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17035382     DOI: 10.1158/1055-9965.EPI-06-0164

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  37 in total

1.  Cancer risks for the relatives of colorectal cancer cases with a methylated MLH1 promoter region: data from the Colorectal Cancer Family Registry.

Authors:  A Joan Levine; Aung Ko Win; Daniel D Buchanan; Mark A Jenkins; John A Baron; Joanne P Young; Tiffany I Long; Daniel J Weisenberger; Peter W Laird; Rebecca L McCall; David J Duggan; Robert W Haile
Journal:  Cancer Prev Res (Phila)       Date:  2011-12-05

Review 2.  Serrated Polyps of Colon and Rectum: a Clinicopathologic Review.

Authors:  Bita Geramizadeh; Scott Robertson
Journal:  J Gastrointest Cancer       Date:  2017-12

3.  The association of lifestyle and dietary factors with the risk for serrated polyps of the colorectum.

Authors:  Kristin Wallace; Maria V Grau; Dennis Ahnen; Dale C Snover; Douglas J Robertson; Daus Mahnke; Jiang Gui; Elizabeth L Barry; Robert W Summers; Gail McKeown-Eyssen; Robert W Haile; John A Baron
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-08       Impact factor: 4.254

Review 4.  Serrated pathway colorectal cancer in the population: genetic consideration.

Authors:  Joanne Young; Mark Jenkins; Susan Parry; Bruce Young; Derek Nancarrow; Dallas English; Graham Giles; Jeremy Jass
Journal:  Gut       Date:  2007-06-12       Impact factor: 23.059

5.  Role of tumour molecular and pathology features to estimate colorectal cancer risk for first-degree relatives.

Authors:  Aung Ko Win; Daniel D Buchanan; Christophe Rosty; Robert J MacInnis; James G Dowty; Gillian S Dite; Graham G Giles; Melissa C Southey; Joanne P Young; Mark Clendenning; Michael D Walsh; Rhiannon J Walters; Alex Boussioutas; Thomas C Smyrk; Stephen N Thibodeau; John A Baron; John D Potter; Polly A Newcomb; Loïc Le Marchand; Robert W Haile; Steven Gallinger; Noralane M Lindor; John L Hopper; Dennis J Ahnen; Mark A Jenkins
Journal:  Gut       Date:  2014-03-10       Impact factor: 23.059

6.  APC and KRAS mutations in distal colorectal polyps are related to smoking habits in men: results of a cross-sectional study.

Authors:  Fernando Martínez; Carlos Fernández-Martos; María Jesús Quintana; Antoni Castells; Antonio Llombart; Francisco Ińiguez; Vicente Guillem; Francisco Dasí
Journal:  Clin Transl Oncol       Date:  2011-09       Impact factor: 3.405

Review 7.  Hereditary and familial colon cancer.

Authors:  Kory W Jasperson; Thérèse M Tuohy; Deborah W Neklason; Randall W Burt
Journal:  Gastroenterology       Date:  2010-06       Impact factor: 22.682

8.  Risk factors for colorectal cancer in patients with multiple serrated polyps: a cross-sectional case series from genetics clinics.

Authors:  Daniel D Buchanan; Kevin Sweet; Musa Drini; Mark A Jenkins; Aung Ko Win; Dallas R English; Michael D Walsh; Mark Clendenning; Diane M McKeone; Rhiannon J Walters; Aedan Roberts; Sally-Ann Pearson; Erika Pavluk; John L Hopper; Michael R Gattas; Jack Goldblatt; Jill George; Graeme K Suthers; Kerry D Phillips; Sonja Woodall; Julie Arnold; Kathy Tucker; Amanda Muir; Michael Field; Sian Greening; Steven Gallinger; Renee Perrier; John A Baron; John D Potter; Robert Haile; Wendy Frankel; Albert de la Chapelle; Finlay Macrae; Christophe Rosty; Neal I Walker; Susan Parry; Joanne P Young
Journal:  PLoS One       Date:  2010-07-16       Impact factor: 3.240

9.  Thrombospondin-4 is a putative tumour-suppressor gene in colorectal cancer that exhibits age-related methylation.

Authors:  Sonia A Greco; June Chia; Kelly J Inglis; Sarah-Jane Cozzi; Ingunn Ramsnes; Ronald L Buttenshaw; Kevin J Spring; Glen M Boyle; Daniel L Worthley; Barbara A Leggett; Vicki L J Whitehall
Journal:  BMC Cancer       Date:  2010-09-16       Impact factor: 4.430

10.  Incorporation of somatic BRAF mutation testing into an algorithm for the investigation of hereditary non-polyposis colorectal cancer.

Authors:  M B Loughrey; P M Waring; A Tan; M Trivett; S Kovalenko; V Beshay; M-A Young; G McArthur; A Boussioutas; A Dobrovic
Journal:  Fam Cancer       Date:  2007-04-24       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.